Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (396)	3/29/1999 3:04:00 PM
From: LLCF	Read Replies (1) \| Respond to of 712

< I have gone over the 10K several times and while I like it, I can't find anything new that would account for the rise.> Yea, there was nothing new that made it go down either! ;). <Find it interesting that there are no post on the CORR board even with the rise in price and volume.> Theres no one left daytrading many biotech stocks... try AMGN. :) DAK

To: aknahow who wrote (396)	3/30/1999 11:17:00 AM
From: Edscharp	Respond to of 712

From MTSL - March 25, 1999 "Despite the substantial sell off in COR Therapeutics' stock over the last couple of weeks, it held very well on the very weak day the market had on Tuesday, a clear indication that we are more than likely near the bottom. We had a discussion with the company today, and are under the impression that sales of Integrilin have increased since the meeting of the American College of Cardiology. We are confident that the company is going to beat the Street's estimates of $60 million in revenues for the year. Do not miss this tremendous opportunity, as they seldom get more attractive than this one. Corr is a buy under $18."